Triple Negative Breast Cancer Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeut

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Triple Negative Breast Cancer pipeline constitutes 75+ key companies continuously working towards developing 80+ Triple Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Triple Negative Breast Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.

The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
• Triple Negative Breast Cancer companies working in the treatment market are ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others, are developing therapies for the Triple Negative Breast Cancer treatment
• Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years.
• In June 2023, Gilead Sciences awarded the first "Toward Health Equity for Black People Impacted by Triple Negative Breast Cancer Resource Hub" grant to TOUCH, The Black Breast Cancer Alliance, in partnership with the Triple Negative Breast Cancer Foundation, the American Association for Cancer Research (AACR), and Nueva Vida for their project Black TNBC Matters.
• In May 2023, The supplemental new drug application ("sNDA") for Shanghai Junshi Biosciences Co., Ltd.'s anti-PD-1 monoclonal antibody, toripalimab, has been accepted by the National Medical Products Administration. The drug is intended to be used in conjunction with albumin-bound paclitaxel to treat PD-L1 positive (CPS ≥ 1) untreated metastatic or recurrent metastatic triple-negative breast cancer.
• In May 2023, The announcement was made by Eisai Co., Ltd. and Bliss Biopharmaceutical (Hangzhou) Co., Ltd. on the cooperative development agreement for BB-1701, an antibody-drug conjugate (ADC) with option rights for strategic partnership. In compliance with the terms of the joint development agreement, Eisai will carry out a Phase II clinical trial for breast cancer, pay BlissBio upfront and development milestones, and acquire the option rights to develop and market BB-1701 internationally, with the exception of Greater China (China, Hong Kong, Macau, Taiwan).
• In May 2023, AML and breast cancer will be treated with gamma-delta T cells (gdTc) thanks to a research collaboration agreement CytoMed Therapeutics Limited signed with The University of Texas MD Anderson Cancer Center ("MD Anderson") in Houston, Texas. The goal of this partnership is to provide patients with breast cancer and AML with novel, reasonably priced therapy options that address their unmet requirements.
• In March 2023, The outcomes of the phase II umbrella study FUTURE, which looked at whether the subtyping-based approach may help patients with metastatic TNBC, were revealed. Enrolled in seven parallel arms were 141 patients with a median of three prior lines of therapy in the metastatic scenario.
• In March 2023, The in-license of Amgen's sovilnesib (AMG650), an oral, first-in-class small molecule inhibitor of KIF18A, has been completed, according to Volastra Therapeutics. The business has also concluded a $60 million Series A investment round. Volastra is granted an exclusive worldwide license (excluding China) to develop and market sovilnesib in accordance with the conditions of the licensing agreement. Amgen gets upfront cash and shares in exchange for royalties and downstream milestones. The medication is presently being studied in Phase 1 for the treatment of solid tumors with TP53 mutations, triple-negative breast cancer, and high-grade serous ovarian cancer that is resistant to platinum.
• In February 2023, Topline results from an interim analysis of the phase 3 TORCHLIGHT trial (NCT04085276) showed a significant improvement in progression-free survival (PFS) compared with placebo and nab-paclitaxel in PD-L1-positive patients with stage IV or recurrent/metastatic triple-negative breast cancer (TNBC), according to Junshi Biosciences, which announced the pre-specified interim analysis. Regardless of PD-L1 status, researchers also noted a significant trend toward enhanced overall survival (OS), a crucial secondary end criterion, with the combination. There were no new signals identified, and toripalimab's safety profile matched its established profile.

Triple Negative Breast Cancer Overview
Triple Negative Breast Cancer (TNBC) is characterized by a tumor that has negative levels of estrogen and progesterone (ER/PR), as determined by immunohistochemistry (IHC), and neither immunohistochemistry (IHC) nor fluorescence in situ hybridization (FISH) has detected overxpression of the HER2 gene.

Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:
• mRNA-2752: ModernaTX, Inc.
• OTS167PO: OncoTherapy Science
• PMD-026: Phoenix Molecular Designs
• X4P-001: Abbisko Therapeutics
• BLEX 404: BioLite, Inc.
• ZEN003694 +Talazoparib: Zenith Epigenetics
• mprime PGG: HiberCell, Inc.
• IPI-549: Infinity Pharmaceuticals
• Trilaciclib: G1 Therapeutics, Inc
• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd
• HLX10: Shanghai Henlius Biotech

Triple Negative Breast Cancer Route of Administration
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Triple Negative Breast Cancer Molecule Type
Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Triple Negative Breast Cancer Pipeline Therapeutics Assessment
• Triple Negative Breast Cancer Assessment by Product Type
• Triple Negative Breast Cancer By Stage and Product Type
• Triple Negative Breast Cancer Assessment by Route of Administration
• Triple Negative Breast Cancer By Stage and Route of Administration
• Triple Negative Breast Cancer Assessment by Molecule Type
• Triple Negative Breast Cancer by Stage and Molecule Type

DelveInsight's Triple Negative Breast Cancer Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:
Key companies developing therapies for Triple Negative Breast Cancer are - ModernaTX, Inc, NuGenerx Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.

Triple Negative Breast Cancer Pipeline Analysis:
The Triple Negative Breast Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
• Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Triple Negative Breast Cancer Pipeline Market Drivers
• Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.

Triple Negative Breast Cancer Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.

Scope of Triple Negative Breast Cancer Pipeline Drug Insight
• Coverage: Global
• Key Triple Negative Breast Cancer Companies: ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others
• Key Triple Negative Breast Cancer Therapies: mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others
• Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
• Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers

Request for Sample PDF Report for Triple Negative Breast Cancer Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Triple Negative Breast Cancer Report Introduction
2. Triple Negative Breast Cancer Executive Summary
3. Triple Negative Breast Cancer Overview
4. Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. Triple Negative Breast Cancer Pipeline Therapeutics
6. Triple Negative Breast Cancer Late Stage Products (Phase II/III)
7. Triple Negative Breast Cancer Mid Stage Products (Phase II)
8. Triple Negative Breast Cancer Early Stage Products (Phase I)
9. Triple Negative Breast Cancer Preclinical Stage Products
10. Triple Negative Breast Cancer Therapeutics Assessment
11. Triple Negative Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Triple Negative Breast Cancer Key Companies
14. Triple Negative Breast Cancer Key Products
15. Triple Negative Breast Cancer Unmet Needs
16 . Triple Negative Breast Cancer Market Drivers and Barriers
17. Triple Negative Breast Cancer Future Perspectives and Conclusion
18. Triple Negative Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Triple Negative Breast Cancer Market https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Triple Negative Breast Cancer Epidemiology https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Triple Negative Breast Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.